| Rank | % of international placing | % of global offering |
|---|---|---|
| 前1名 | — | — |
The IPO saw extraordinary market enthusiasm with an oversubscription ratio of 6238.42x, indicating intense demand for the shares. The overall hit rate of just 3.32% reflects a very low allocation probability for retail investors, typical of highly sought-after biotech listings under Chapter 18A. Final pricing at HK$33.37 likely captured strong institutional interest, though the absence of an indicative range limits pricing insight. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier-specific allocation data is not provided, preventing any analysis of distribution patterns or potential anomalies such as 甲尾-乙头 inefficiencies. Without detailed breakdowns of lots applied and allocated per tier, it is impossible to assess broker fee efficiency or unusual winner ratios at key thresholds. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
The demographic data for this IPO is not available; all recorded percentages for mainland and Hong Kong participation show zero, likely indicating missing or unreported figures. Consequently, no conclusions can be drawn about regional concentration, gender distribution, or Mainland China participation rates. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
This page shows allotment analysis for Vigonvita-B (02630): one-lot hit rate, Pool A/B allotment distribution, oversubscription multiple, and grey-market and first-day performance. Data is parsed from the HKEX allotment results announcement. How allotment rates and clawback work is explained in How Hong Kong IPO Allotment Rates Work.

